CureVac Down 52% After Hours on Interim Covid-19 Vaccine Study Data
16 Junio 2021 - 4:55PM
Noticias Dow Jones
By Josh Beckerman
CureVac NV shares fell 52% to $45.45 in after-hours trading as
the company reported unfavorable interim data from a Covid-19
vaccine clinical trial.
"In the unprecedented context of at least 13 variants
circulating within the study population subset assessed at this
interim analysis, CVnCoV demonstrated an interim vaccine efficacy
of 47% against COVID-19 disease of any severity and did not meet
prespecified statistical success criteria," CureVac said.
The HERALD study, conducted by CureVac in conjunction with
Bayer, enrolled about 40,000 people in 10 countries in Latin
America and Europe.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 16, 2021 17:40 ET (21:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Bayer (TG:BAYN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
